Wunderlich Securities bought a new position in shares of Allergan, Inc. (NYSE:AGN) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 800 shares of the company’s stock, valued at approximately $250,000.

Several other hedge funds have also recently modified their holdings of AGN. Eagle Asset Management raised its stake in shares of Allergan by 59.8% in the third quarter. Eagle Asset Management now owns 521,342 shares of the company’s stock worth $141,704,000 after buying an additional 195,104 shares during the period. Gerstein Fisher raised its stake in shares of Allergan by 20.8% in the third quarter. Gerstein Fisher now owns 21,766 shares of the company’s stock worth $5,916,000 after buying an additional 3,748 shares during the period. MUFG Americas raised its stake in shares of Allergan by 26.1% in the third quarter. MUFG Americas now owns 16,460 shares of the company’s stock worth $4,474,000 after buying an additional 3,411 shares during the period. Saturna Capital raised its stake in shares of Allergan by 43.5% in the third quarter. Saturna Capital now owns 3,452 shares of the company’s stock worth $938,000 after buying an additional 1,047 shares during the period. Finally, Harvest Management raised its stake in shares of Allergan by 81.8% in the third quarter. Harvest Management now owns 2,000 shares of the company’s stock worth $544,000 after buying an additional 900 shares during the period.

Shares of Allergan, Inc. (NYSE:AGN) traded up 0.76% during midday trading on Friday, reaching $298.04. The company had a trading volume of 2,089,645 shares. The company has a 50 day moving average price of $304.90 and a 200-day moving average price of $301.94. Allergan, Inc. has a one year low of $237.50 and a one year high of $340.34. The firm has a market capitalization of $117.46 billion and a P/E ratio of 27.40.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $3.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.18 by $0.30. The business earned $4.10 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the previous year, the business posted $1.78 EPS. Allergan’s revenue was up 90.1% compared to the same quarter last year. On average, analysts anticipate that Allergan, Inc. will post $15.43 EPS for the current fiscal year.

Several analysts recently issued reports on the company. Citigroup Inc. reiterated a “buy” rating on shares of Allergan in a report on Thursday, November 19th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $400.00 target price on shares of Allergan in a report on Sunday, November 1st. Vetr upgraded Allergan from a “buy” rating to a “strong-buy” rating and set a $323.33 target price on the stock in a report on Wednesday, January 13th. Leerink Swann reiterated an “outperform” rating and set a $393.00 target price (up previously from $355.00) on shares of Allergan in a report on Wednesday, December 2nd. Finally, S&P Equity Research reiterated a “buy” rating and set a $385.00 target price on shares of Allergan in a report on Friday, October 30th. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $367.08.

In related news, Director Nesli Basgoz sold 2,300 shares of the firm’s stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $312.96, for a total value of $719,808.00. Following the transaction, the director now owns 4,062 shares of the company’s stock, valued at approximately $1,271,243.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (NYSE:AGN) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

12 Month Chart for NYSE:AGN

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Allergan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.